{"transactions":[{"id":4623725,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-21T22:21:29.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":1279,"price":69.5696,"value":88979.5184,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":495686,"source":{"system":"sec-edgar","filing":"0001470831-26-000897","document":"wk-form4_1790029286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000897/wk-form4_1790029286.xml","form_type":"4"}},{"id":4623724,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-21T22:21:29.000Z","date":"2026-09-17","kind":"sale","planned":true,"acquired":false,"shares":8721,"price":69.0136,"value":601867.6056,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":496965,"source":{"system":"sec-edgar","filing":"0001470831-26-000897","document":"wk-form4_1790029286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000897/wk-form4_1790029286.xml","form_type":"4"}},{"id":679964,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":100,"price":85.65,"value":8565.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":505686,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679963,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":84.6867,"value":152436.06,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":505786,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679962,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":8100,"price":83.8588,"value":679256.28,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":507586,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679961,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":1199,"price":83.7732,"value":100444.0668,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":243327,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679960,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":14602,"price":82.9922,"value":1211852.1044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":244526,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679959,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":17279,"price":82.2104,"value":1420513.5016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":259128,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":679958,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:31:26.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":81.1494,"value":154183.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":276407,"source":{"system":"sec-edgar","filing":"0001470831-26-000848","document":"wk-form4_1787257884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000848/wk-form4_1787257884.xml","form_type":"4"}},{"id":683607,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":6520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":91274,"derivative":{"underlying":"Common Stock","underlying_shares":6520},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683606,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":11554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":115538,"derivative":{"underlying":"Common Stock","underlying_shares":11554},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683605,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":19599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":117596,"derivative":{"underlying":"Common Stock","underlying_shares":19599},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683604,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":false,"shares":33544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":67088,"derivative":{"underlying":"Common Stock","underlying_shares":33544},"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683603,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":36237,"price":79.86,"value":2893886.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,217 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":278307,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683602,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":6520,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":314544,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683601,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":11554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":308024,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683600,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":19599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":296470,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":683599,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T22:02:32.000Z","date":"2026-08-16","kind":"exercise","planned":false,"acquired":true,"shares":33544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":276871,"source":{"system":"sec-edgar","filing":"0001470831-26-000836","document":"wk-form4_1787090549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000836/wk-form4_1787090549.xml","form_type":"4"}},{"id":732281,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:53:23.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276033/ownership.xml","form_type":"4"}},{"id":746261,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":4415,"price":68.9593,"value":304455.3095,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4318447,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746260,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":8437,"price":67.8848,"value":572744.0576,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4322862,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746259,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7148,"price":67.199,"value":480338.452,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4331299,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746258,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":4416,"price":68.9593,"value":304524.2688,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":515686,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746257,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":8437,"price":67.8848,"value":572744.0576,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":520102,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746256,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":7147,"price":67.199,"value":480271.253,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":528539,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746255,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":450,"price":68.2697,"value":30721.365,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4338447,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746254,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":15921,"price":67.7377,"value":1078451.9217,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4338897,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746253,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":1429,"price":66.723,"value":95347.167,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4354818,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746252,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":65.7202,"value":144584.44,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4356247,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746251,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":450,"price":68.2697,"value":30721.365,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":535686,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746250,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":15921,"price":67.7378,"value":1078453.5138,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":536136,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746249,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":1429,"price":66.723,"value":95347.167,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":552057,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":746248,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-08T22:01:32.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":65.7202,"value":144584.44,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":553486,"source":{"system":"sec-edgar","filing":"0001470831-26-000523","document":"wk-form4_1780956089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/wk-form4_1780956089.xml","form_type":"4"}},{"id":763869,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":800,"price":70.9189,"value":56735.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":243327,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763868,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":11250,"price":70.4814,"value":792915.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":244127,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763867,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":5072,"price":69.2235,"value":351101.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":255377,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763866,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":6725,"price":68.3025,"value":459334.3125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":260449,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":763865,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:54:16.000Z","date":"2026-05-21","kind":"sale","planned":true,"acquired":false,"shares":2256,"price":67.5687,"value":152434.9872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":267174,"source":{"system":"sec-edgar","filing":"0001470831-26-000488","document":"wk-form4_1779828852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/wk-form4_1779828852.xml","form_type":"4"}},{"id":772167,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":6519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":97794,"derivative":{"underlying":"Common Stock","underlying_shares":6519},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772166,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":11553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":127092,"derivative":{"underlying":"Common Stock","underlying_shares":11553},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772165,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":19599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":137195,"derivative":{"underlying":"Common Stock","underlying_shares":19599},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772164,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":false,"shares":33544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":100632,"derivative":{"underlying":"Common Stock","underlying_shares":33544},"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772163,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":36236,"price":66.13,"value":2396286.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,215 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":269430,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772162,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":true,"shares":6519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":305666,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772161,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":true,"shares":11553,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":299147,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772160,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":true,"shares":19599,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":287594,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":772159,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:27:55.000Z","date":"2026-05-16","kind":"exercise","planned":false,"acquired":true,"shares":33544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":267995,"source":{"system":"sec-edgar","filing":"0001470831-26-000472","document":"wk-form4_1779222471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000472/wk-form4_1779222471.xml","form_type":"4"}},{"id":784811,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":950,"price":68.3477,"value":64930.315,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4358447,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784810,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":5076,"price":67.3455,"value":341845.758,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4359397,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784809,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":13974,"price":66.6505,"value":931374.087,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4364473,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784808,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":950,"price":68.3477,"value":64930.315,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $68.17 to $68.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":555686,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784807,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":5077,"price":67.3455,"value":341913.1035,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $67.10 to $68.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":556636,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784806,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":13973,"price":66.6505,"value":931307.4365,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $66.10 to $67.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":561713,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784805,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":449,"price":69.0911,"value":31021.9039,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4378447,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784804,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":8334,"price":68.3775,"value":569858.085,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4378896,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784803,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":11217,"price":67.4949,"value":757090.2933,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4387230,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784802,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":450,"price":69.0911,"value":31090.995,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $69.02 to $69.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":575686,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784801,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":8333,"price":68.3775,"value":569789.7075,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $68.02 to $69.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":576136,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":784800,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-11T21:15:29.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":11217,"price":67.495,"value":757091.415,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $67.02 to $68.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":584469,"source":{"system":"sec-edgar","filing":"0001470831-26-000423","document":"wk-form4_1778534126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000423/wk-form4_1778534126.xml","form_type":"4"}},{"id":809645,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":74.6038,"value":1492076.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of the shares sold from $74.27 to $75.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4398447,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809644,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":74.6048,"value":1492096.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $74.26 to $75.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":595686,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809643,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":7800,"price":75.5287,"value":589123.86,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $75.18 to $76.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4418447,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809642,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":5128,"price":74.5669,"value":382379.0632,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $74.18 to $75.145 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4426247,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809641,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":7072,"price":73.6427,"value":520801.1744,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $73.15 to $74.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4431375,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809640,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":75.5548,"value":566661.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $75.22 to $76.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":615686,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809639,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":5300,"price":74.6044,"value":395403.32,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $74.19 to $75.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":623186,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":809638,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-13T22:06:06.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":7200,"price":73.6444,"value":530239.68,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $73.19 to $74.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":628486,"source":{"system":"sec-edgar","filing":"0001470831-26-000361","document":"wk-form4_1776117963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000361/wk-form4_1776117963.xml","form_type":"4"}},{"id":824176,"issuer":{"id":1775,"kind":"organization","name":"Maze Therapeutics, Inc.","symbol":"MAZE"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-31T20:13:50.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":33417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":33417,"derivative":{"exercise_price":30.38,"expiration_date":"2036-03-26","underlying":"Common Stock","underlying_shares":33417},"source":{"system":"sec-edgar","filing":"0001742485-26-000003","document":"form4-03312026_080346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742485/000174248526000003/form4-03312026_080346.xml","form_type":"4"}},{"id":833537,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-19T20:28:10.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":104313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date."}],"balance_after":104313,"derivative":{"underlying":"Common Stock","underlying_shares":104313},"source":{"system":"sec-edgar","filing":"0001470831-26-000296","document":"wk-form4_1773952086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000296/wk-form4_1773952086.xml","form_type":"4"}},{"id":833536,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-19T20:28:10.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":40570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date."}],"balance_after":40570,"derivative":{"exercise_price":70.94,"expiration_date":"2036-03-16","underlying":"Common Stock","underlying_shares":40570},"source":{"system":"sec-edgar","filing":"0001470831-26-000296","document":"wk-form4_1773952086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000296/wk-form4_1773952086.xml","form_type":"4"}},{"id":841682,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":9759,"price":69.2251,"value":675567.7509,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of the shares sold from $68.82 to $69.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4438447,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841681,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":10241,"price":68.3864,"value":700345.1224,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of the shares sold from $67.82 to $68.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4448206,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841680,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":10310,"price":69.1997,"value":713448.907,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $68.76 to $69.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":635686,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841679,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":9690,"price":68.3634,"value":662441.346,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $67.76 to $68.74 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":645996,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841678,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":300,"price":70.15,"value":21045.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4458447,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841677,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":5815,"price":69.2913,"value":402928.9095,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $68.94 to $69.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4458747,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841676,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":13885,"price":68.4686,"value":950686.511,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $67.935 to $68.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4464562,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841675,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":300,"price":70.15,"value":21045.0,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $70.1 to $70.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":655686,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841674,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":5363,"price":69.3176,"value":371750.2888,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $68.94 to $69.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":655986,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":841673,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-16T22:05:14.000Z","date":"2026-03-12","kind":"sale","planned":true,"acquired":false,"shares":14337,"price":68.4808,"value":981809.2296,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $67.935 to $68.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":661349,"source":{"system":"sec-edgar","filing":"0001470831-26-000275","document":"wk-form4_1773698710.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000275/wk-form4_1773698710.xml","form_type":"4"}},{"id":888164,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:32:04.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":602,"price":72.801,"value":43826.202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":234451,"source":{"system":"sec-edgar","filing":"0001470831-26-000214","document":"wk-form4_1771882321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000214/wk-form4_1771882321.xml","form_type":"4"}},{"id":888163,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:32:04.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":8528,"price":72.0804,"value":614701.6512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":235053,"source":{"system":"sec-edgar","filing":"0001470831-26-000214","document":"wk-form4_1771882321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000214/wk-form4_1771882321.xml","form_type":"4"}},{"id":888162,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-23T21:32:04.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":18923,"price":71.0347,"value":1344189.6281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":243581,"source":{"system":"sec-edgar","filing":"0001470831-26-000214","document":"wk-form4_1771882321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000214/wk-form4_1771882321.xml","form_type":"4"}},{"id":896961,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":11554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":138645,"derivative":{"underlying":"Common Stock","underlying_shares":11554},"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896960,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":19600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":156794,"derivative":{"underlying":"Common Stock","underlying_shares":19600},"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896959,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":false,"shares":33544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023.  Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.  The RSUs have no expiration date."}],"balance_after":134176,"derivative":{"underlying":"Common Stock","underlying_shares":33544},"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896958,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":30970,"price":75.25,"value":2330492.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,698 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":262504,"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896957,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":11554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":293474,"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896956,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":19600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":281920,"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":896955,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:41:47.000Z","date":"2026-02-16","kind":"exercise","planned":false,"acquired":true,"shares":33544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":262320,"source":{"system":"sec-edgar","filing":"0001470831-26-000188","document":"wk-form4_1771458104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000188/wk-form4_1771458104.xml","form_type":"4"}},{"id":907663,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":3961,"price":73.2505,"value":290145.2305,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents the weighted average sale price of the shares sold from $73.1 to $73.4 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4478447,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907662,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":4404,"price":72.6472,"value":319938.2688,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the weighted average sale price of the shares sold from $72.1 to $73.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4482408,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907661,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":3775,"price":71.4581,"value":269754.3275,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of the shares sold from $71.1 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4486812,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907660,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":7860,"price":70.7005,"value":555705.93,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4490587,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907659,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":3994,"price":73.2535,"value":292574.479,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of the shares sold from $73.09 to $73.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":675686,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907658,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":4484,"price":72.635,"value":325695.34,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of the shares sold from $72.09 to $73.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":679680,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907657,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":3716,"price":71.4416,"value":265476.9856,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of the shares sold from $71.09 to $72.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":684164,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907656,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":7806,"price":70.6887,"value":551795.9922,"ownership":{"direct":false,"nature":"By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of the shares sold from $70.09 to $71.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":687880,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907655,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-10","kind":"sale","planned":true,"acquired":false,"shares":5960,"price":72.2737,"value":430751.252,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of the shares sold from $72.02 to $72.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4498447,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}},{"id":907654,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-12T21:39:55.000Z","date":"2026-02-10","kind":"sale","planned":true,"acquired":false,"shares":14040,"price":71.7953,"value":1008006.012,"ownership":{"direct":false,"nature":"By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold from $71.02 to $72.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."}],"balance_after":4504407,"source":{"system":"sec-edgar","filing":"0001470831-26-000118","document":"wk-form4_1770932392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000118/wk-form4_1770932392.xml","form_type":"4"}}],"next_cursor":"2026-02-12T21:39:55.000000Z,907654"}